As historically, pediatric clinical drug trials have been scarce for obvious ethical, practical, scientific and financial reasons, and drugs are understudied in children. This lack of knowledge on how to dose drugs optimally in children has been acknowledged by EU and US lawmakers and since a few years regulations are in place to stimulate drug studies in this population.
Due to the historical neglect to study drugs in children, both academia and industry, are less experienced and organized to conduct these studies, when compared to the adult world.
Hence, there is a need for both expertise and logistic support to conduct pediatric drug trials successfully.
The mission of the MCRN 2012 is to foster high-quality research on drugs in children in the Netherlands, to ultimately improve drug therapy in this population by providing expertise and to coordinate logistical support to academic investigators as well as to farmaceutical industries and contract research organisations.